ScreenerHero

VRCI Verici Dx plc

LSE · GB · Healthcare · Diagnostics & Research · vericidx.com
0.2250GBp0.00%Mkt Cap: 5.59M $P/E: —

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transp…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$250.23BUSDP/E 36.4
DHR
Danaher Corporation
$155.51BUSDP/E 39.4
NTRA
Natera, Inc.
$61.35BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc.
$48.29BUSDP/E 33.8
ILMN
Illumina, Inc.
$44.35BUSDP/E 54.8
IQV
IQVIA Holdings Inc.
$43.80BUSDP/E 33.1
WAT
Waters Corporation
$43.21BUSDP/E 111.4
IDXX
IDEXX Laboratories, Inc.
$41.58BUSDP/E 37.0
MTD
Mettler-Toledo International Inc.
$30.89BUSDP/E 34.7
DGX
Quest Diagnostics Incorporated
$25.63BUSDP/E 24.7
GH
Guardant Health, Inc.
$25.12BUSD
LH
Labcorp Holdings Inc.
$25.03BUSDP/E 25.5
RVTY
Revvity, Inc.
$17.56BUSDP/E 75.3
MEDP
Medpace Holdings, Inc.
$17.32BUSDP/E 36.4
CRL
Charles River Laboratories International, Inc.
$14.84BUSD
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
ICLR
ICON Public Limited Company
$12.99BUSDP/E 177.2
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V.
$9.46BUSDP/E 23.2

Key Statistics

Company
Market Cap5.59M USD
Enterprise Value2.01M USD
Revenue (TTM)3.83M USD
Gross Profit3.08M USD
Net Income (TTM)-7.54M USD
Revenue/Share0.0020 GBp
Last Price0.2250 GBp
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees23
CountryGB
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.25
EV/Revenue0.53
P/S1.46
P/B0.76
EPS (TTM)0.00
EPS (Forward)0.00
52W Range
0.19434% of range0.9940
52W High0.9940 GBp
52W Low0.1943 GBp
Profitability
Gross Margin77.46%
Oper. Margin-226.31%
EBITDA Margin-207.69%
Profit Margin-189.22%
ROE-106.58%
ROA-87.32%
Growth
Revenue Growth-7.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.98M USD
CapEx (TTM)205.43K USD
FCF Margin-166.39%
FCF Yield-113.87%
Net Debt-1.77M USD
Net Debt/EBITDA0.22
Balance Sheet
Debt/Equity0.03
Current Ratio2.81
Quick Ratio2.53
Book Value/Sh0.0030 GBp
Cash/Share0.0020 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 GBp
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.900 GBp
Upside (mean)+1188.9%
Target Range2.900 GBp – 2.900 GBp
# Analysts1
Ownership
Shares Out.2.29B
Float1.25B
Insiders1.33%
Institutions80.41%
Technical
SMA 500.2361 (-4.7%)
SMA 2000.4549 (-50.5%)
Beta1.22
S&P 52W Chg14.58%
Avg Vol (30d)792.77K
Avg Vol (10d)1.22M
Technical Indicators
RSI (14)40.4
MACD-0.0081
MACD Signal-0.0108
MACD Hist.+0.0027
BB Upper0.2310 GBp
BB Middle0.2243 GBp
BB Lower0.2175 GBp
BB Width5.98%
ATR (14)0.0441 GBp
Vol Ratio (20d)0.00x